Literature DB >> 34226736

The Tuberculosis Drug Accelerator at year 10: what have we learned?

Bree B Aldridge1, David Barros-Aguirre2, Clifton E Barry3, Robert H Bates2, Steven J Berthel4, Helena I Boshoff3, Kelly Chibale5, Xin-Jie Chu6, Christopher B Cooper7, Véronique Dartois8, Ken Duncan9, Nader Fotouhi7, Fabian Gusovsky10, Philip A Hipskind11, Dale J Kempf12, Joël Lelièvre2, Anne J Lenaerts13, Case W McNamara14, Valerie Mizrahi5, Carl Nathan15, David B Olsen16, Tanya Parish17, H Michael Petrassi14, Alexander Pym18, Kyu Y Rhee19, Gregory T Robertson13, Jeremy Michael Rock20, Eric J Rubin21, Betsy Russell22, David G Russell23, James C Sacchettini24, Dirk Schnappinger19, Michael Schrimpf12, Anna M Upton25, Peter Warner9, Paul Graham Wyatt26, Ying Yuan6.   

Abstract

Entities:  

Year:  2021        PMID： 34226736     DOI： 10.1038/s41591-021-01442-2

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis.

Authors:  Jian Xu; Paul J Converse; Anna M Upton; Khisimuzi Mdluli; Nader Fotouhi; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191
  1 in total
  10 in total

1.  Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).

Authors:  Pooja V Hegde; Michael D Howe; Matthew D Zimmerman; Helena I M Boshoff; Sachin Sharma; Brianna Remache; Ziyi Jia; Yan Pan; Anthony D Baughn; Veronique Dartois; Courtney C Aldrich
Journal:  Eur J Med Chem       Date:  2022-02-19       Impact factor: 6.514

2.  Surmounting structural barriers to tackle endemic infectious diseases.

Authors:  Felix Calderón; Alan H Fairlamb; Mike Strange; Pauline Williams; Carl F Nathan
Journal:  J Exp Med       Date:  2021-08-19       Impact factor: 14.307

Review 3.  Anti-tuberculosis treatment strategies and drug development: challenges and priorities.

Authors:  Véronique A Dartois; Eric J Rubin
Journal:  Nat Rev Microbiol       Date:  2022-04-27       Impact factor: 78.297

4.  Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.

Authors: 
Journal:  Eur Respir J       Date:  2022-04-14       Impact factor: 33.795

5.  DNA-Dependent Binding of Nargenicin to DnaE1 Inhibits Replication in Mycobacterium tuberculosis.

Authors:  Melissa D Chengalroyen; Mandy K Mason; Alessandro Borsellini; Raffaella Tassoni; Garth L Abrahams; Sasha Lynch; Yong-Mo Ahn; Jon Ambler; Katherine Young; Brendan M Crowley; David B Olsen; Digby F Warner; Clifton E Barry Iii; Helena I M Boshoff; Meindert H Lamers; Valerie Mizrahi
Journal:  ACS Infect Dis       Date:  2022-02-10       Impact factor: 5.084

6.  Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.

Authors:  Ben Gold; Jun Zhang; Landys Lopez Quezada; Julia Roberts; Yan Ling; Madeleine Wood; Wasima Shinwari; Laurent Goullieux; Christine Roubert; Laurent Fraisse; Eric Bacqué; Sophie Lagrange; Bruno Filoche-Rommé; Michal Vieth; Philip A Hipskind; Louis N Jungheim; Jeffrey Aubé; Sarah M Scarry; Stacey L McDonald; Kelin Li; Andrew Perkowski; Quyen Nguyen; Véronique Dartois; Matthew Zimmerman; David B Olsen; Katherine Young; Shilah Bonnett; Douglas Joerss; Tanya Parish; Helena I Boshoff; Kriti Arora; Clifton E Barry; Laura Guijarro; Sara Anca; Joaquín Rullas; Beatriz Rodríguez-Salguero; Maria S Martínez-Martínez; Esther Porras-De Francisco; Monica Cacho; David Barros-Aguirre; Paul Smith; Steven J Berthel; Carl Nathan; Robert H Bates
Journal:  ACS Infect Dis       Date:  2022-02-22       Impact factor: 5.084

7.  Dehydroquinate Synthase Directly Binds to Streptomycin and Regulates Susceptibility of Mycobacterium bovis to Streptomycin in a Non-canonical Mode.

Authors:  Wenping Wei; Junjie Qiao; Xiaofang Jiang; Luxia Cai; Xiaomin Hu; Jin He; Min Chen; Min Yang; Tao Cui
Journal:  Front Microbiol       Date:  2022-04-19       Impact factor: 5.640

Review 8.  Chemical and Pharmacological Properties of Decoquinate: A Review of Its Pharmaceutical Potential and Future Perspectives.

Authors:  Tainá Santos Souza; Diogo Rodrigo Magalhães Moreira; Henrique Rodrigues Marcelino
Journal:  Pharmaceutics       Date:  2022-06-30       Impact factor: 6.525

9.  Innovation Experiences from Africa-Led Drug Discovery at the Holistic Drug Discovery and Development (H3D) Centre.

Authors:  Vinayak Singh; Dickson Mambwe; Constance Mawunyo Korkor; Kelly Chibale
Journal:  ACS Med Chem Lett       Date:  2022-07-11       Impact factor: 4.632

10.  Design principles to assemble drug combinations for effective tuberculosis therapy using interpretable pairwise drug response measurements.

Authors:  Jonah Larkins-Ford; Yonatan N Degefu; Nhi Van; Artem Sokolov; Bree B Aldridge
Journal:  Cell Rep Med       Date:  2022-09-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.